These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
159 related items for PubMed ID: 1631793
21. [Recombinant tissue-type plasminogen activator: pharmacokinetics and effect on the hemostasis system of the human]. Seifried E, Böck F, Tanswell P, Rijken DC, Kluft C, Heimpel H. Klin Wochenschr; 1988; 66 Suppl 12():40-9. PubMed ID: 2450222 [Abstract] [Full Text] [Related]
22. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator. Watahiki Y, Scully MF, Ellis V, Kakkar VV. Thromb Haemost; 1989 Jun 30; 61(3):502-6. PubMed ID: 2508259 [Abstract] [Full Text] [Related]
30. Fibrin affinity and clearance of t-PA deletion and substitution analogues. Johannessen M, Diness V, Pingel K, Petersen LC, Rao D, Lioubin P, O'Hara P, Mulvihill E. Thromb Haemost; 1990 Feb 19; 63(1):54-9. PubMed ID: 2111048 [Abstract] [Full Text] [Related]
31. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model. Collen D, Stassen JM, De Cock F. Thromb Haemost; 1987 Oct 28; 58(3):943-6. PubMed ID: 3124288 [Abstract] [Full Text] [Related]
32. Biochemical properties of recombinant mutants of nonglycosylated single chain urokinase-type plasminogen activator. Li XK, Lijnen HR, Nelles L, Hu MH, Collen D. Biochim Biophys Acta; 1992 Sep 04; 1159(1):37-43. PubMed ID: 1390910 [Abstract] [Full Text] [Related]
33. Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase. Holvoet P, Laroche Y, Stassen JM, Lijnen HR, Van Hoef B, De Cock F, Van Houtven A, Gansemans Y, Matthyssens G, Collen D. Blood; 1993 Feb 01; 81(3):696-703. PubMed ID: 8427962 [Abstract] [Full Text] [Related]
36. Direct microscopic monitoring of initial and dynamic clot lysis using plasmin or rt-PA in an in vitro flow system. Bizjak N, Bajd F, Vidmar J, Blinc A, Perme MP, Marder VJ, Novokhatny V, Serša I. Thromb Res; 2014 May 01; 133(5):908-13. PubMed ID: 24613694 [Abstract] [Full Text] [Related]
37. Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits. Collen D, Stassen JM, Larsen G. Blood; 1988 Jan 01; 71(1):216-9. PubMed ID: 3120823 [Abstract] [Full Text] [Related]
38. Thrombolytic profiles of clot-targeted plasminogen activators. Parameters determining potency and initial and maximal rates. Holvoet P, Dewerchin M, Stassen JM, Lijnen HR, Tollenaere T, Gaffney PJ, Collen D. Circulation; 1993 Mar 01; 87(3):1007-16. PubMed ID: 8443877 [Abstract] [Full Text] [Related]
39. The position of the structurally autonomous kringle 2 domain influences the functional features of tissue-type plasminogen activator. Bakker AH, Rehberg EF, Marotti KR, Verheijen JH. Protein Eng; 1995 Mar 01; 8(3):293-300. PubMed ID: 7479691 [Abstract] [Full Text] [Related]